Data from 2015 CROI: Treatment with a TLR7 Agonist Induces Transient Viremia in SIV-infected-ART-Suppressed Monkey
Interesting data presented this morning at the 2015 CROI in Seattle regarding a new compound developed by Gilead to target the reservoir.
The compound called GS-9620 is an orally given TLR7 agonist.
-NK cells and CD8 T cells activation
-activation of CD4 T cells.
Ten indian Rhesus macaques were infected by intra rectal administration of SIVmac251.
ART was initiated at day 65 (Tenofovir, FTC, Dolutegravir).
At day 320: 4 animals received the tool compound and 6 the placebo.
Transient viremia was observed in the compound receivers. There was identity between these "viral blips" and virus sequences from PBMCs, lymph nodes and colon.
SIV DNA was reduced in TLR7 agonist treated animals on cART (in 3 out of 4 actually).
No difference in plasma kinetics after stopping cART was observed between the 2 groups BUT LOWER PLASMA VIRUS SET POINTS were obtained in TLR7 agonist treated animals compared to controls.
Key words: GS-9620, HIV persistence, HIV reservoir, SIV, TLR7 agonist, gilead